Q32 Bio Statistics

Total Valuation

Q32 Bio has a market cap or net worth of $223.32 million. The enterprise value is $186.21 million.

Market Cap	223.32M
Enterprise Value	186.21M

Important Dates

The next estimated earnings date is Wednesday, August 5, 2026, before market open.

Earnings Date	Aug 5, 2026
Ex-Dividend Date	n/a

Share Statistics

Q32 Bio has 16.96 million shares outstanding. The number of shares has increased by 5.51% in one year.

Current Share Class	16.96M
Shares Outstanding	16.96M
Shares Change (YoY)	+5.51%
Shares Change (QoQ)	+11.93%
Owned by Insiders (%)	0.71%
Owned by Institutions (%)	20.85%
Float	1.55M

Valuation Ratios

The trailing PE ratio is 5.08.

PE Ratio	5.08
Forward PE	n/a
PS Ratio	4.16
Forward PS	223.32
PB Ratio	4.16
P/TBV Ratio	4.82
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	5.60
EV / Sales	3.47
EV / EBITDA	8.55
EV / EBIT	8.70
EV / FCF	n/a

Financial Position

The company has a current ratio of 5.36, with a Debt / Equity ratio of 0.29.

Current Ratio	5.36
Quick Ratio	4.81
Debt / Equity	0.29
Debt / EBITDA	0.58
Debt / FCF	n/a
Interest Coverage	21.41

Financial Efficiency

Return on equity (ROE) is 157.18% and return on invested capital (ROIC) is 35.80%.

Return on Equity (ROE)	157.18%
Return on Assets (ROA)	18.75%
Return on Invested Capital (ROIC)	35.80%
Return on Capital Employed (ROCE)	40.39%
Weighted Average Cost of Capital (WACC)	3.15%
Revenue Per Employee	$2.44M
Profits Per Employee	$1.51M
Employee Count	22
Asset Turnover	0.75
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +744.23% in the last 52 weeks. The beta is -0.23, so Q32 Bio's price volatility has been lower than the market average.

Beta (5Y)	-0.23
52-Week Price Change	+744.23%
50-Day Moving Average	8.69
200-Day Moving Average	4.95
Relative Strength Index (RSI)	61.03
Average Volume (20 Days)	573,841

Short Selling Information

The latest short interest is 861,749, so 5.08% of the outstanding shares have been sold short.

Short Interest	861,749
Short Previous Month	632,722
Short % of Shares Out	5.08%
Short % of Float	55.72%
Short Ratio (days to cover)	0.66

Income Statement

In the last 12 months, Q32 Bio had revenue of $53.74 million and earned $33.24 million in profits. Earnings per share was $2.59.

Revenue	53.74M
Gross Profit	38.49M
Operating Income	21.41M
Pretax Income	33.24M
Net Income	33.24M
EBITDA	21.77M
EBIT	21.41M
Earnings Per Share (EPS)	$2.59

Full Income Statement

Balance Sheet

The company has $50.75 million in cash and $13.65 million in debt, giving a net cash position of $37.11 million or $2.19 per share.

Cash & Cash Equivalents	50.75M
Total Debt	13.65M
Net Cash	37.11M
Net Cash Per Share	$2.19
Equity (Book Value)	46.31M
Book Value Per Share	3.17
Working Capital	46.53M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-27.40M
Capital Expenditures	n/a
Depreciation & Amortization	362,000
Net Borrowing	-4.69M
Free Cash Flow	-27.40M
FCF Per Share	-$1.62

Full Cash Flow Statement

Margins

Gross margin is 71.62%, with operating and profit margins of 39.84% and 61.86%.

Gross Margin	71.62%
Operating Margin	39.84%
Pretax Margin	61.86%
Profit Margin	61.86%
EBITDA Margin	40.51%
EBIT Margin	39.84%
FCF Margin	n/a

Dividends & Yields

Q32 Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-5.51%
Shareholder Yield	-5.51%
Earnings Yield	14.89%
FCF Yield	-12.27%

Analyst Forecast

The average price target for Q32 Bio is $14.25, which is 8.20% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$14.25
Price Target Difference	8.20%
Analyst Consensus	Strong Buy
Analyst Count	5
Revenue Growth Forecast (3Y)	-66.61%
EPS Growth Forecast (3Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Q32 Bio has an Altman Z-Score of -0.61 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.61
Piotroski F-Score	4